RxDoctor Payments DataLook up a doctor →

Luis Diaz, MD

Neurology · Las Vegas, NVNPI 1457356461

Payments from drug & device makers

$17,054in general payments, 2019–2025

Across 915 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • AbbVie$2K
  • Amgen$1K
  • Novartis$1K
  • Genentech USA, Inc.$1K
  • AstraZeneca$1K
  • plus $8K from 51 others

What the payments were for

  • Speaking & faculty fees$760%
  • Food & beverage$16,89599%
  • Education$820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen175$2,333
AbbVie(2 entities)115$1,740
Amgen(2 entities)60$1,482
Novartis79$1,291
Genentech USA, Inc.64$1,163
AstraZeneca39$1,067
EMD Serono, Inc.51$975
Acadia Pharmaceuticals Inc40$616
Sanofi23$496
UCB, Inc.19$463
Lundbeck LLC17$369
Medtronic(2 entities)13$335
SK Life Science, Inc.17$320
Tersera Therapeutics LLC12$286
Pfizer14$273
Merz Pharmaceuticals, LLC13$272
Mallinckrodt Hospital Products Inc.11$270
Bristol Myers Squibb3$266
Mallinckrodt Enterprises LLC9$209
Biohaven Pharmaceuticals, Inc.14$208
Octapharma USA, Inc.9$206
Biohaven Pharmaceutical Holding Company Ltd.13$204
Sanofi-aventis U.S. LLC8$185
Merz North America, Inc.7$172
TG Therapeutics, Inc.5$156
E.r. Squibb & Sons, L.L.C.2$131
MDD US Operations, LLC7$131
Alnylam Pharmaceuticals Inc.7$128
Akcea Therapeutics, Inc.6$127
Adamas Pharmaceuticals, Inc.5$88
Takeda Pharmaceuticals U.S.A., Inc.6$83
Acorda Therapeutics, Inc5$76
Argenx US, Inc.3$71
Kyowa Kirin, Inc.3$70
Johnson & Johnson(2 entities)4$69
Neurelis, Inc.3$66
ANI Pharmaceuticals, Inc.3$65
Upsher-smith Laboratories LLC3$60
Harmony Biosciences LLC2$58
Assertio Therapeutics, Inc.3$48
Abbott2$43
Boston Scientific2$40
Grifols USA, LLC2$40
Vertical Pharmaceuticals, LLC2$37
Alkermes, Inc.2$31
Neurocrine Biosciences, Inc.1$27
Soleno Therapeutics, Inc.1$26
Zyla Life Sciences, Inc.2$25
Avion Pharmaceuticals1$24
Shire North American Group Inc1$22
Axsome Therapeutics, Inc.1$19
Lilly USA, LLC1$18
Corcept Therapeutics1$18
Eisai Inc.1$18
Arbor Pharmaceuticals, Inc.1$17
Avanir Pharmaceuticals, Inc.1$13
Teva Pharmaceuticals USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,054 in reported general payments places this provider in the 75th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$9,918,126
Medicare patients
426
Services billed
153,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab31$273,798
GammakedImmune Globul G/Gly/Iga Avg 4627$203,392
NuplazidPimavanserin Tartrate35$188,515
TecfideraDimethyl Fumarate12$110,165
VumerityDiroximel Fumarate12$101,528
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5025$82,387
UbrelvyUbrogepant40$48,471
XcopriCenobamate44$48,343
Aimovig AutoinjectorErenumab-Aooe45$35,948
EliquisApixaban41$25,992
NeuproRotigotine18$19,482
XareltoRivaroxaban27$14,909
AptiomEslicarbazepine Acetate12$13,914
Nurtec OdtRimegepant Sulfate11$11,921
Lacosamide97$9,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$2,333$211,69324 claims
Acadia Pharmaceuticals IncNuplazid$616$188,51535 claims
AbbVieUbrelvy$1,740$48,47140 claims
SK Life Science, Inc.Xcopri$320$48,34344 claims
PfizerEliquis, Nurtec Odt$273$37,91252 claims
UCB, Inc.Neupro$463$19,48218 claims
Johnson & JohnsonXarelto$69$14,90927 claims
Upsher-smith Laboratories LLCTopiramate$60$8511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →